Skip to main content

Table 3 Clinical features of ESHF patients according to sample groups

From: Uncovering the cathepsin system in heart failure patients submitted to Left Ventricular Assist Device (LVAD) implantation

 

Pre-LVAD (n = 22)

HT Patient (n = 7)

P Value*

Post-LVAD (n = 6)

P Value†

Age, years

58 (48–64)

55 (46–62)

0.459

44 (41–51)

0.031

Male gender, n (%)

19 (86)

5 (71)

0.569

6 (100)

1.000

Etiology, n (%)

-

-

0.202

-

0.673

IDC

12 (55)

6 (86)

 

45 (67)

 

IHD

10 (46)

1 (14)

 

2 (33)

 

Treatments, n (%)

-

-

 

-

 

ACE-I and/or ARB

13 (59)

5 (71)

0.677

4 (67)

1.000

Beta-blockers

16 (80)

5 (71)

0.633

4 (67)

0.596

Statins

6 (27)

2 (29)

1.000

-

0.284

Antiplatelet agents

12 (54)

2 (29)

0.390

6 (100)§

0.062

Inotropic support

11 (50)

1 (14)

0.187

2 (33)

0.655

Creatinine, mg/dL

1.08 (0.9-1.53)

1.32 (1.00-1.78)

0.313

0.95 (0.83-1.48)

0.599

t-Bil, mg/dL

1.43 (0.55-1.90)

0.76 (0.48-1.14)

0.212

0.79 (0.62-1.35)

0.199

NT-proBNP, ng/L

2838 (1371–6042)

2389 (840–5762)

0.522

599 (158–1036)

0.007

LVEF, %

23 (19–25)

28 (20–29)

0.220

32 (20–33)

0.104

LVEDV, mL

202 (173–291)

228 (206–300)

0.185

237 (178–260)

0.820

LVEDD, mm

67 (57–71)

70 (68–79)

0.132

68 (60–75)

0.633

RAP, mmHg

5 (3–10)

3 (2–5)

0.074

3 (2–6)

0.969

PCWP, mmHg

25 (17–31)

11 (4–20)

0.019

10 (3–13)

0.023

CI, L/min/m 2

1.7 (1.4-2.2)

2.0 (1.5-2.7)

0.362

3.0 (2.2-3.3)

0.085

PAPs, mmHg

55 (42–63)

28 (19–42)

0.012

29 (21–33)

0.006

  1. Data are expressed as median (25th-75th percentile) or frequency (percentage). ACE, angiotensin converting enzyme; ARB; angiotensin receptor blockers; CI, cardiac index; IDC, idiopathic dilated cardiomyopathy; IHD, ischemic heart disease; LVEDD, left ventricular end-diastolic diameter; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; PAPs: pulmonary systolic arterial pressure; PCWP, pulmonary capillary wedge pressure; RAP, right atrial pressure; t-Bil, total bilirubin; P Value* pre-LVAD group vs HT group; P Value† pre-LVAD group vs post-LVAD group; §P <0.05 vs HT group.